SMP National Resource Center

March 5, 2021

Court documents say Allergy and Asthma Associates Inc. (AAA) submitted improper billings to Medicare and Medicaid for Xolair, an expensive asthma treatment sold in single-use vials. In situations where a patient’s dose resulted in a leftover partial vial of Xolair, AAA administered the leftover amount to another patient and then billed Medicare and Medicaid for administering this amount as if it were the entire single-use vial. Read a news story and a Department of Justice press release.


SMP National Resource Center